Literature DB >> 3085680

Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases.

C R Wolf, J S Macpherson, J F Smyth.   

Abstract

The metabolism of mitozantrone, a chemotherapeutic agent used in the treatment of breast cancer, has been studied in vitro using rat liver subcellular fractions. This compound would appear to be metabolized by two interesting pathways. One involves conjugation with glucuronic acid, catalyzed most effectively by a 3-methylcholanthrene-inducible glucuronosyl transferase. The other pathway appears to be a glutathione conjugation reaction which requires prior metabolism by cytochrome P-450. The reaction with glutathione appears to be enzymatic as 1-chloro-2,4-dinitrobenzene was a potent inhibitor of this reaction. Liver cytosol did not enhance the microsomal rate of glutathione-conjugate formation, suggesting an important role for the microsomal glutathione transferases in the disposition of this compound. The relationship between these reactions and the mode of action of mitozantrone is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085680     DOI: 10.1016/0006-2952(86)90127-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents.

Authors:  R B Puchalski; W E Fahl
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

2.  Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.

Authors:  A Feofanov; S Sharonov; F Fleury; I Kudelina; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

Review 3.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 4.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

5.  Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells.

Authors:  Ana Reis-Mendes; Félix Carvalho; Fernando Remião; Emília Sousa; Maria de Lourdes Bastos; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2022-10-10       Impact factor: 6.168

6.  Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey.

Authors:  S L Berg; F M Balis; K S Godwin; D G Poplack
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

7.  Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).

Authors:  S K Frank; D A Mathiesen; M Szurszewski; M J Kuffel; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 8.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells.

Authors:  S J Duthie; M H Grant
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

10.  Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases.

Authors:  W H Peters; H M Roelofs; W L van Putten; J B Jansen; J G Klijn; J A Foekens
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.